Cargando…
Differences in the renal antifibrotic signaling of serelaxin and zaprinast
Autores principales: | Wetzl, Veronika, Faerber, Lothar, Hofmann, Franz, Schinner, Elisabeth, Schlossmann, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565091/ http://dx.doi.org/10.1186/2050-6511-16-S1-A99 |
Ejemplares similares
-
Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin
por: Wetzl, Veronika, et al.
Publicado: (2016) -
Antifibrotic function of cGKI in the kidney
por: Schlossmann, Jens, et al.
Publicado: (2015) -
Cyclic nucleotide signalling in kidney fibrosis
por: Schinner, Elisabeth, et al.
Publicado: (2015) -
Inhibition of the TGFβ signalling pathway by cGMP and cGMP‐dependent kinase I in renal fibrosis
por: Schinner, Elisabeth, et al.
Publicado: (2017) -
Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
por: Bennett, Robert G, et al.
Publicado: (2017)